Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed in centers affiliated to the French Intergroup of Myeloproliferative neoplasms. In this study, we report their long-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ianotto, Jean-Christophe, Chauveau, Aurélie, Boyer-Perrard, Françoise, Gyan, Emmanuel, Laribi, Kamel, Cony-Makhoul, Pascale, Demory, Jean-Loup, de Renzis, Benoit, Dosquet, Christine, Rey, Jerome, Roy, Lydia, Dupriez, Brigitte, Knoops, Laurent, Legros, Laurence, Malou, Mohamed, Hutin, Pascal, Ranta, Dana, Benbrahim, Omar, Ugo, Valérie, Lippert, Eric, Kiladjian, Jean-Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830374/
https://www.ncbi.nlm.nih.gov/pubmed/29217781
http://dx.doi.org/10.3324/haematol.2017.181297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830374/
https://www.ncbi.nlm.nih.gov/pubmed/29217781
http://dx.doi.org/10.3324/haematol.2017.181297

Ejemplares similares